153 related articles for article (PubMed ID: 12048682)
21. UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status.
Husain A; Yan XJ; Rosales N; Aghajanian C; Schwartz GK; Spriggs DR
Clin Cancer Res; 1997 Nov; 3(11):2089-97. PubMed ID: 9815601
[TBL] [Abstract][Full Text] [Related]
22. Radiosensitivity of human breast cancer cells transduced with wild-type p53 gene is influenced by the p53 status of parental cells.
Maeda T; Matsubara H; Koide Y; Sugaya M; Miyazawa Y; Tasaki K; Isono K; Ochiai T; Sakiyama S; Tagawa M
Anticancer Res; 2000; 20(2A):869-74. PubMed ID: 10810368
[TBL] [Abstract][Full Text] [Related]
23. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
[TBL] [Abstract][Full Text] [Related]
24. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma.
Mezzanzanica D; Balladore E; Turatti F; Luison E; Alberti P; Bagnoli M; Figini M; Mazzoni A; Raspagliesi F; Oggionni M; Pilotti S; Canevari S
Clin Cancer Res; 2004 Aug; 10(15):5202-14. PubMed ID: 15297424
[TBL] [Abstract][Full Text] [Related]
25. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells.
Abedini MR; Muller EJ; Brun J; Bergeron R; Gray DA; Tsang BK
Cancer Res; 2008 Jun; 68(12):4511-7. PubMed ID: 18559494
[TBL] [Abstract][Full Text] [Related]
27. [Reversal of drug resistance in human ovarian cancer cells by wild-type PTEN gene and its mechanisms].
Wu HJ; Wu HT; Weng DH; Xing H; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):612-6. PubMed ID: 17983517
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of protein kinase Cdelta enhances cisplatin-induced cytotoxicity correlated with p53 in gastric cancer cell line.
Iioka Y; Mishima K; Azuma N; Tsuchida A; Takagi Y; Aoki T; Saito I
Pathobiology; 2005; 72(3):152-9. PubMed ID: 15860933
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
30. Restoration of wild-type p53 activity enhances the sensitivity of pleural metastasis to cisplatin through an apoptotic mechanism.
Riva CM
Anticancer Res; 2000; 20(6B):4463-71. PubMed ID: 11205289
[TBL] [Abstract][Full Text] [Related]
31. Expression of p53 protein as a predictor of the response to 5-fluorouracil and cisplatin chemotherapy in human gastrointestinal cancer cell lines evaluated with apoptosis by use of thin layer collagen gel.
Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S
Int J Oncol; 2004 Apr; 24(4):807-13. PubMed ID: 15010816
[TBL] [Abstract][Full Text] [Related]
32. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
[TBL] [Abstract][Full Text] [Related]
33. In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice.
Collinet P; Vereecque R; Sabban F; Vinatier D; Leblanc E; Narducci F; Querleu D; Quesnel B
J Obstet Gynaecol Res; 2006 Oct; 32(5):449-53. PubMed ID: 16984510
[TBL] [Abstract][Full Text] [Related]
34. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
35. Clonal heterogeneity of p53 mutations in ovarian cancer.
Manahan KJ; Taylor DD; Gerçel-Taylor C
Int J Oncol; 2001 Aug; 19(2):387-94. PubMed ID: 11445857
[TBL] [Abstract][Full Text] [Related]
36. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.
Wolf JK; Mills GB; Bazzet L; Bast RC; Roth JA; Gershenson DM
Gynecol Oncol; 1999 Nov; 75(2):261-6. PubMed ID: 10525383
[TBL] [Abstract][Full Text] [Related]
37. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
[TBL] [Abstract][Full Text] [Related]
38. Growth of human tumor cells in macroporous microcarriers results in p53-independent, decreased cisplatin sensitivity relative to monolayers.
Maurer BJ; Ihnat MA; Morgan C; Pullman J; O'Brien C; Johnson SW; Rasey JS; Cornwell MM
Mol Pharmacol; 1999 May; 55(5):938-47. PubMed ID: 10220573
[TBL] [Abstract][Full Text] [Related]
39. Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines.
Concin N; Stimpfl M; Zeillinger C; Wolff U; Hefler L; Sedlak J; Leodolter S; Zeillinger R
Int J Oncol; 2003 Jan; 22(1):51-7. PubMed ID: 12469184
[TBL] [Abstract][Full Text] [Related]
40. 14-3-3sigma-dependent resistance to cisplatin.
Han Z; Dimas K; Tian X; Wang Y; Hemmi H; Yamada K; Kato N; Pantazis P; Ramanujam RJ; Anant S; Wyche JH; Houchen CW
Anticancer Res; 2009 Jun; 29(6):2009-14. PubMed ID: 19528459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
